Centrin-1 Antibody Specificity via CDR Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current detection and treatment of pancreatic and prostate cancers are hindered by the lack of specificity of available anti-Centrin-1 antibodies, which fail to distinguish between Centrin-1 and Centrin-2, due to their high homology, leading to ineffective biomarker detection and treatment.
Innovation Solution
Development of Centrin-1 antibodies that exhibit specific binding to Centrin-1 with reduced or no binding to Centrin-2, including monoclonal, polyclonal, and humanized antibodies with optimized variable regions and complementarity-determining regions (CDRs) for enhanced specificity and affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-Centrin-1 antibodies are used for cancer detection and treatment, then general binding to Centrin-1 is achieved, but specificity is lost due to cross-reactivity with Centrin-2
Solution Approach 1:
The patent applies local quality by engineering antibodies with specifically optimized complementarity-determining regions (CDRs) that recognize unique local epitopes on Centrin-1. The variable regions are designed to interact with specific amino acid sequences in Centrin-1 that are not present or are different in Centrin-2, thereby achieving localized specific binding that distinguishes between the two highly homologous proteins.
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequences of the antibody variable regions, particularly the CDRs, to alter binding characteristics. Through sequence optimization and selection of specific CDR combinations, the antibodies achieve enhanced affinity for Centrin-1 while reducing cross-reactivity with Centrin-2, despite the 80% homology between the two proteins.
2Measurement precision
If antibodies with high affinity for Centrin-1 are developed, then detection sensitivity is improved, but cross-reactivity with Centrin-2 increases due to high homology
Solution Approach 1:
The patent applies segmentation by dividing the antibody structure into distinct functional regions, particularly focusing on the variable regions and CDRs. By optimizing specific CDR segments (CDR1, CDR2, CDR3 of both heavy and light chains) independently, the patent achieves high overall affinity for Centrin-1 while maintaining specificity. This segmented approach allows fine-tuning of binding properties without affecting the entire antibody structure.
Solution Approach 2:
The patent employs composite materials by creating antibodies with composite variable region structures that combine multiple optimized CDR sequences. The heavy chain variable region and light chain variable region are composed of specific CDR combinations that work together synergistically to achieve both high affinity and high specificity, effectively distinguishing Centrin-1 from Centrin-2.
Data Source
AI summary
Provided herein are antibodies that specifically bind Centrin-1 and methods of making the same, for use the treatment, prevention, detection, imaging, and diagnosis of cancers including pancreatic and prostate cancer.